|
New Approaches to HDL modification
|
|
|
The Inhibition of Cholesterol Ester Transfer Protein
|
|
|
CETP Levels and CAD risk:
|
|
|
Rationale
|
|
|
RADIANCE 1 and 2 Study Designs
|
|
|
RADIANCE 1
|
|
|
RADIANCE 2
|
|
|
RADIANCE 1- Heterozygous FH Adverse Events (All Causality)
|
|
|
ILLUMINATE
|
|
|
ILLUMINATE: Long-term Outcomes in Patients With CHD or CHD Risk Equivalence
|
|
|
On Trial Lipid Levels By Study Month
|
|
|
Primary Endpoint ILLUMINATE: Time to First MCVE: Kaplan-Meier Plot
|
|
|
Scientific Case for Developing the CETP inhibitor Anacetrapib
|
|
|
Anacetrapib Dose Ranging Study
|
|
|
Effect of HDL from Anacetrapib-treated Patients
(300 mg) on Cholesterol Efflux from Human Macrophages
|
|
|
Effect of Torcetrapib and Anacetrapib on
Blood Pressure in Rhesus Monkeys
|
|
|
The Effect of Torcetrapib and Anacetrapib on Aldosterone
Secretion from Primary Rat Adrenocortical Cells
|
|
|
Development Strategy for Anacetrapib
|
|
|
Anacetrapib Program Timelines
|
|
|
Phase II/III: DEFINE, The Anacetrapib
Safety study
|
|
Share this page with your colleagues and friends: